The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family
Open accessAbstract
Cytokines in the tumor necrosis factor (TNF) family regulate development and function of the immune system. We have isolated a new member of this family, designated Apo-2 ligand (Apo-2L), via an expressed sequence tag. Apo-2L is a 281-amino acid protein, related most closely to Fas/Apo-1 ligand. Transfected Apo-2L is expressed at the cell surface with its C terminus exposed, indicating a type II transmembrane protein topology. Like Fas/Apo-1 ligand and TNF, the C-terminal extracellular region of Apo-2L (amino acids 114-281) exhibits a homotrimeric subunit structure. Soluble Apo-2L induces extensive apoptosis in lymphoid as well as non-lymphoid tumor cell lines. The effect of Apo-2L is not inhibited by soluble Fas/Apo-1 and TNF receptors; moreover, expression of human Fas/Apo-1 in mouse fibroblasts, which confers sensitivity to induction of apoptosis by agonistic anti-Fas/Apo-1 antibody, does not confer sensitivity to Apo-2L. Hence, Apo-2L acts via a receptor which is distinct from Fas/Apo-1 and TNF receptors. These results suggest that, along with other family members such as Fas/Apo-1 ligand and TNF, Apo-2L may serve as an extracellular signal that triggers programmed cell death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nagata, S., & Golstein, P. (1995) · Science · doi:10.1126/science.7533326 · Cited by 3,979
Fadok, V. A., Voelker, D. R., Campbell, P. A., Cohen, J. J., Bratton, D. L., & Henson, P. M. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.7.2207 · Cited by 3,316
Koopman, G., Reutelingsperger, C., Kuijten, G., Keehnen, R., Pals, S., & van Oers, M. (1994) · Blood · doi:10.1182/blood.v84.5.1415.1415 · Cited by 2,681
Social controls on cell survival and cell death
Raff, M. C. (1992) · Nature · doi:10.1038/356397a0 · Cited by 2,604
Mechanisms and Genes of Cellular Suicide
Steller, H. (1995) · Science · doi:10.1126/science.7878463 · Cited by 2,479
Baculovirus expression vectors: a laboratory manual.
O’Reilly, D. R., Miller, L. K., & Luckow, V. A. (1992) · Oxford University Press eBooks · Cited by 2,242
The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death
Smith, C. A., Farrah, T., & Goodwin, R. G. (1994) · Cell · doi:10.1016/0092-8674(94)90372-7 · Cited by 1,887
An analysis of vertebrate mRNA sequences: intimations of translational control.
Kozak, M. (1991) · The Journal of cell biology · doi:10.1083/jcb.115.4.887 · Cited by 1,635
Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)
Dhein, J., Walczak, H., Bäumler, C., Debatin, K.-M., & Krammer, P. H. (1995) · Nature · doi:10.1038/373438a0 · Cited by 1,609
Yonehara, S., Ishii, A., & Yonehara, M. (1989) · The Journal of experimental medicine · doi:10.1084/jem.169.5.1747 · Cited by 1,400
Cited by
Death Receptors: Signaling and Modulation
Ashkenazi, A., & Dixit, V. M. (1998) · Science · doi:10.1126/science.281.5381.1305 · Cited by 5,866
Self-citationOsteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Signalling pathways of the TNF superfamily: a double-edged sword
Aggarwal, B. B. (2003) · Nature Reviews Immunology · doi:10.1038/nri1184 · Cited by 2,793
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497
Safety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
Self-citationGerber, H.-P., McMurtrey, A., Kowalski, J., Yan, M., Keyt, B. A., Dixit, V., & Ferrara, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.46.30336 · Cited by 1,981
The Receptor for the Cytotoxic Ligand TRAIL
Pan, G., O'Rourke, K., Chinnaiyan, A. M., Gentz, R., Ebner, R., Ni, J., & Dixit, V. M. (1997) · Science · doi:10.1126/science.276.5309.111 · Cited by 1,767
Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors
Sheridan, J. P., Marsters, S. A., Pitti, R. M., Gurney, A., Skubatch, M., Baldwin, D., Ramakrishnan, L., Gray, C. L., Baker, K., Wood, W. I., et al. (1997) · Science · doi:10.1126/science.277.5327.818 · Cited by 1,664
Self-citationAn Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL
Pan, G., Ni, J., Wei, Y.-F., Yu, G.-L., Gentz, R., & Dixit, V. M. (1997) · Science · doi:10.1126/science.277.5327.815 · Cited by 1,496
Targeting death and decoy receptors of the tumour-necrosis factor superfamily
Ashkenazi, A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc821 · Cited by 1,360
Self-citationApoptosis control by death and decoy receptors
Ashkenazi, A., & Dixit, V. M. (1999) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(99)80034-9 · Cited by 1,288
Self-citationOsteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL
Emery, J. G., McDonnell, P., Burke, M. B., Deen, K. C., Lyn, S., Silverman, C., Dul, E., Appelbaum, E. R., Eichman, C., DiPrinzio, R., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14363 · Cited by 1,184
TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL
Walczak, H. (1997) · The EMBO Journal · doi:10.1093/emboj/16.17.5386 · Cited by 1,130
Wong, B. R., Rho, J., Arron, J., Robinson, E., Orlinick, J., Chao, M., Kalachikov, S., Cayani, E., Bartlett, F. S., Frankel, W. N., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.40.25190 · Cited by 1,042
Apo2L/TRAIL-Dependent Recruitment of Endogenous FADD and Caspase-8 to Death Receptors 4 and 5
Kischkel, F. C., Lawrence, D. A., Chuntharapai, A., Schow, P., Kim, K. J., & Ashkenazi, A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80212-5 · Cited by 975
Self-citationApoptosis and apoptotic body: disease message and therapeutic target potentials
Xu, X., Lai, Y., & Hua, Z.-C. (2019) · Bioscience Reports · doi:10.1042/bsr20180992 · Cited by 909
Apo2L/TRAIL and its death and decoy receptors
LeBlanc, H. N., & Ashkenazi, A. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401187 · Cited by 854
Self-citationJo, M., Kim, T.-H., Seol, D.-W., Esplen, J. E., Dorko, K., Billiar, T. R., & Strom, S. C. (2000) · Nature Medicine · doi:10.1038/75045 · Cited by 843
The TRAIL apoptotic pathway in cancer onset, progression and therapy
Johnstone, R. W., Frew, A. J., & Smyth, M. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2465 · Cited by 834
Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis
Chawla-Sarkar, M., Lindner, D. J., Liu, Y.-F., Williams, B. R., Sen, G. C., Silverman, R. H., & Borden, E. C. (2003) · Apoptosis · doi:10.1023/a:1023668705040 · Cited by 829
Degli-Esposti, M. A., Dougall, W. C., Smolak, P. J., Waugh, J. Y., Smith, C. A., & Goodwin, R. G. (1997) · Immunity · doi:10.1016/s1074-7613(00)80399-4 · Cited by 821
Apoptosis: Basic Mechanisms and Implications for Cardiovascular Disease
Haunstetter, A., & Izumo, S. (1998) · Circulation Research · doi:10.1161/01.res.82.11.1111 · Cited by 807
Sprick, M. R., Weigand, M. A., Rieser, E., Rauch, C. T., Juo, P., Blenis, J., Krammer, P. H., & Walczak, H. (2000) · Immunity · doi:10.1016/s1074-7613(00)80211-3 · Cited by 794
Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer
Pitti, R. M., Marsters, S. A., Lawrence, D. A., Roy, M., Kischkel, F. C., Dowd, P., Huang, A., Donahue, C. J., Sherwood, S. W., Baldwin, D. T., et al. (1998) · Nature · doi:10.1038/25387 · Cited by 783
Self-citationTakeda, K., Hayakawa, Y., Smyth, M. J., Kayagaki, N., Yamaguchi, N., Kakuta, S., Iwakura, Y., Yagita, H., & Okumura, K. (2001) · Nature Medicine · doi:10.1038/83416 · Cited by 775
Apoptosis and cancer: the genesis of a research field
Cotter, T. G. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2663 · Cited by 758
Mechanisms of resistance to TRAIL-induced apoptosis in cancer
Zhang, L., & Fang, B. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700792 · Cited by 702
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
Lawrence, D., Shahrokh, Z., Marsters, S., Achilles, K., Shih, D., Mounho, B., Hillan, K., Totpal, K., DeForge, L., Schow, P., et al. (2001) · Nature Medicine · doi:10.1038/86397 · Cited by 702
Self-citationTRAIL Receptors 1 (DR4) and 2 (DR5) Signal FADD-Dependent Apoptosis and Activate NF-κB
Schneider, P., Thome, M., Burns, K., Bodmer, J.-L., Hofmann, K., Kataoka, T., Holler, N., & Tschopp, J. (1997) · Immunity · doi:10.1016/s1074-7613(00)80401-x · Cited by 696
Life and death by death receptors
Guicciardi, M. E., & Gores, G. J. (2009) · The FASEB Journal · doi:10.1096/fj.08-111005 · Cited by 690
Intracellular Regulation of TRAIL-Induced Apoptosis in Human Melanoma Cells
Griffith, T. S., Chin, W. A., Jackson, G. C., Lynch, D. H., & Kubin, M. Z. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.6.2833 · Cited by 664
Signal Transduction by DR3, a Death Domain-Containing Receptor Related to TNFR-1 and CD95
Chinnaiyan, A. M., O'Rourke, K., Yu, G.-L., Lyons, R. H., Garg, M., Duan, D. R., Xing, L., Gentz, R., Ni, J., & Dixit, V. M. (1996) · Science · doi:10.1126/science.274.5289.990 · Cited by 654
A novel receptor for Apo2L/TRAIL contains a truncated death domain
Marsters, S. A., Sheridan, J. P., Pitti, R. M., Huang, A., Skubatch, M., Baldwin, D., Yuan, J., Gurney, A., Goddard, A. D., Godowski, P., et al. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00422-2 · Cited by 653
Self-citationWang, J., Zheng, L., Lobito, A., Chan, F. K.-M., Dale, J., Sneller, M., Yao, X., Puck, J. M., Straus, S. E., & Lenardo, M. J. (1999) · Cell · doi:10.1016/s0092-8674(00)80605-4 · Cited by 640
The CD95 (APO-1/Fas) and the TRAIL (APO-2L) Apoptosis Systems
Walczak, H., & Krammer, P. H. (2000) · Experimental Cell Research · doi:10.1006/excr.2000.4840 · Cited by 628
CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death
Janssen, E. M., Droin, N. M., Lemmens, E. E., Pinkoski, M. J., Bensinger, S. J., Ehst, B. D., Griffith, T. S., Green, D. R., & Schoenberger, S. P. (2005) · Nature · doi:10.1038/nature03337 · Cited by 619
Major apoptotic mechanisms and genes involved in apoptosis
Kiraz, Y., Adan, A., Kartal Yandim, M., & Baran, Y. (2016) · Tumor Biology · doi:10.1007/s13277-016-5035-9 · Cited by 582
Zamai, L., Ahmad, M., Bennett, I. M., Azzoni, L., Alnemri, E. S., & Perussia, B. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2375 · Cited by 566
Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL
MacFarlane, M., Ahmad, M., Srinivasula, S. M., Fernandes-Alnemri, T., Cohen, G. M., & Alnemri, E. S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.41.25417 · Cited by 557
Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy
von Karstedt, S., Montinaro, A., & Walczak, H. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.28 · Cited by 556
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy
Almasan, A., & Ashkenazi, A. (2003) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(03)00029-7 · Cited by 553
Self-citationKischkel, F. C., Lawrence, D. A., Tinel, A., LeBlanc, H., Virmani, A., Schow, P., Gazdar, A., Blenis, J., Arnott, D., & Ashkenazi, A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105102200 · Cited by 536
Self-citationRaimondo, S., Naselli, F., Fontana, S., Monteleone, F., Lo Dico, A., Saieva, L., Zito, G., Flugy, A., Manno, M., Di Bella, M. A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4004 · Cited by 521
Smyth, M. J., Cretney, E., Takeda, K., Wiltrout, R. H., Sedger, L. M., Kayagaki, N., Yagita, H., & Okumura, K. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.6.661 · Cited by 512
APRIL, a New Ligand of the Tumor Necrosis Factor Family, Stimulates Tumor Cell Growth
Hahne, M., Kataoka, T., Schröter, M., Hofmann, K., Irmler, M., Bodmer, J.-L., Schneider, P., Bornand, T., Holler, N., French, L. E., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.6.1185 · Cited by 506
Caspase-8 and Bid: Caught in the act between death receptors and mitochondria
Kantari, C., & Walczak, H. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.026 · Cited by 502
The TNF Family of Ligands and Receptors: Communication Modules in the Immune System and Beyond
Dostert, C., Grusdat, M., Letellier, E., & Brenner, D. (2019) · Physiological Reviews · doi:10.1152/physrev.00045.2017 · Cited by 498
Kayagaki, N., Yamaguchi, N., Nakayama, M., Eto, H., Okumura, K., & Yagita, H. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.9.1451 · Cited by 479
Monocyte-mediated Tumoricidal Activity via the Tumor Necrosis Factor–related Cytokine, TRAIL
Griffith, T. S., Wiley, S. R., Kubin, M. Z., Sedger, L. M., Maliszewski, C. R., & Fanger, N. A. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.8.1343 · Cited by 476
Takeda, K., Smyth, M. J., Cretney, E., Hayakawa, Y., Kayagaki, N., Yagita, H., & Okumura, K. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011171 · Cited by 465
Mitsiades, C. S., Mitsiades, N., Poulaki, V., Schlossman, R., Akiyama, M., Chauhan, D., Hideshima, T., Treon, S. P., Munshi, N. C., Richardson, P. G., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205664 · Cited by 464
TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO
Deng, Y., Lin, Y., & Wu, X. (2002) · Genes & Development · doi:10.1101/gad.949602 · Cited by 458
TRAIL signalling: Decisions between life and death
Falschlehner, C., Emmerich, C. H., Gerlach, B., & Walczak, H. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.02.007 · Cited by 458
Getting TRAIL back on track for cancer therapy
Lemke, J., von Karstedt, S., Zinngrebe, J., & Walczak, H. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2014.81 · Cited by 457
TRAIL: a molecule with multiple receptors and control mechanisms
Griffith, T. S., & Lynch, D. H. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80224-0 · Cited by 453
Kelley, S. K., Harris, L. A., Xie, D., DeForge, L., Totpal, K., Bussiere, J., & Fox, J. A. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29298-3 · Cited by 445
Hymowitz, S. G., Christinger, H. W., Fuh, G., Ultsch, M., O'Connell, M., Kelley, R. F., Ashkenazi, A., & de Vos, A. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80207-5 · Cited by 435
Self-citationDirecting cancer cells to self-destruct with pro-apoptotic receptor agonists
Ashkenazi, A. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2637 · Cited by 432
Self-citationAshkenazi, A., Holland, P., & Eckhardt, S. G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7198 · Cited by 421
Self-citationSuliman, A., Lam, A., Datta, R., & Srivastava, R. K. (2001) · Oncogene · doi:10.1038/sj.onc.1204282 · Cited by 419
Fanger, N. A., Maliszewski, C. R., Schooley, K., & Griffith, T. S. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.8.1155 · Cited by 413
CD95(APO-1/Fas)-Mediated Apoptosis: Live and Let Die
Krammer, P. H. (1998) · Advances in Immunology · doi:10.1016/s0065-2776(08)60402-2 · Cited by 394
Mitsiades, C. S., Treon, S. P., Mitsiades, N., Shima, Y., Richardson, P., Schlossman, R., Hideshima, T., & Anderson, K. C. (2001) · Blood · doi:10.1182/blood.v98.3.795 · Cited by 392
von Bülow, G.-U., & Bram, R. J. (1997) · Science · doi:10.1126/science.278.5335.138 · Cited by 372
Targeting death receptors in cancer with Apo2L/TRAIL
KELLEY, S. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.02.006 · Cited by 370
Nature's TRAIL—On a Path to Cancer Immunotherapy
Smyth, M. J., Takeda, K., Hayakawa, Y., Peschon, J. J., van den Brink, M. R. M., & Yagita, H. (2003) · Immunity · doi:10.1016/s1074-7613(02)00502-2 · Cited by 366
Takimoto, R., & El-Deiry, W. S. (2000) · Oncogene · doi:10.1038/sj.onc.1203489 · Cited by 360
Chawla-Sarkar, M., Bae, S. I., Reu, F. J., Jacobs, B. S., Lindner, D. J., & Borden, E. C. (2004) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401416 · Cited by 359
New insights into apoptosis signaling by Apo2L/TRAIL
Gonzalvez, F., & Ashkenazi, A. (2010) · Oncogene · doi:10.1038/onc.2010.221 · Cited by 359
Self-citationApoptosis: Programmed cell death at a molecular level
Schultz, D. R., & Harringto, W. J. (2003) · Seminars in Arthritis and Rheumatism · doi:10.1053/sarh.2003.50005 · Cited by 356
Apoptosis: mechanisms and relevance in cancer
Vermeulen, K., Van Bockstaele, D. R., & Berneman, Z. N. (2005) · Annals of Hematology · doi:10.1007/s00277-005-1065-x · Cited by 344
Expression and Function of TNF-Related Apoptosis-Inducing Ligand on Murine Activated NK Cells
Kayagaki, N., Yamaguchi, N., Nakayama, M., Takeda, K., Akiba, H., Tsutsui, H., Okamura, H., Nakanishi, K., Okumura, K., & Yagita, H. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.4.1906 · Cited by 340
Cleavage of Focal Adhesion Kinase by Caspases during Apoptosis
Wen, L.-P., Fahrni, J. A., Troie, S., Guan, J.-L., Orth, K., & Rosen, G. D. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.41.26056 · Cited by 336
Thomas, W. D., & Hersey, P. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.5.2195 · Cited by 326
TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL
Screaton, G. R., Mongkolsapaya, J., Xu, X.-N., Cowper, A. E., McMichael, A. J., & Bell, J. I. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00297-1 · Cited by 325
TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling
Pan, G., Ni, J., Yu, G.-L., Wei, Y.-F., & Dixit, V. M. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00135-5 · Cited by 317
Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κB
Ravi, R., Bedi, G. C., Engstrom, L. W., Zeng, Q., Mookerjee, B., Gélinas, C., Fuchs, E. J., & Bedi, A. (2001) · Nature Cell Biology · doi:10.1038/35070096 · Cited by 312
Activated Human T Cells Release Bioactive Fas Ligand and APO2 Ligand in Microvesicles
Martínez-Lorenzo, M. J., Anel, A., Gamen, S., Monleón, I., Lasierra, P., Larrad, L., Piñeiro, A., Alava, M. A., & Naval, J. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.3.1274 · Cited by 307
Pukac, L., Kanakaraj, P., Humphreys, R., Alderson, R., Bloom, M., Sung, C., Riccobene, T., Johnson, R., Fiscella, M., Mahoney, A., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602487 · Cited by 306
Onto better TRAILs for cancer treatment
de Miguel, D., Lemke, J., Anel, A., Walczak, H., & Martinez-Lostao, L. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2015.174 · Cited by 304
Krakstad, C., & Chekenya, M. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-135 · Cited by 301
Characterization of two receptors for TRAIL1
Schneider, P., Bodmer, J.-L., Thome, M., Hofmann, K., Holler, N., & Tschopp, J. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01231-3 · Cited by 290
TRAIL/Apo-2L: Mechanisms and Clinical Applications in Cancer
Srivastava, R. K. (2001) · Neoplasia · doi:10.1038/sj.neo.7900203 · Cited by 280
Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis
Herr, I. (1997) · The EMBO Journal · doi:10.1093/emboj/16.20.6200 · Cited by 278
Tan, K. B., Harrop, J., Reddy, M., Young, P., Terrett, J., Emery, J., Moore, G., & Truneh, A. (1997) · Gene · doi:10.1016/s0378-1119(97)00509-x · Cited by 277
PROTEOLYTIC ACTIVITIES THAT MEDIATE APOPTOSIS
Kidd, V. J. (1998) · Annual Review of Physiology · doi:10.1146/annurev.physiol.60.1.533 · Cited by 277
Dimberg, L. Y., Anderson, C. K., Camidge, R., Behbakht, K., Thorburn, A., & Ford, H. L. (2013) · Oncogene · doi:10.1038/onc.2012.164 · Cited by 276
TRAIL on trial: preclinical advances in cancer therapy
Stuckey, D. W., & Shah, K. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.08.007 · Cited by 276
Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis
Hinz, S., Trauzold, A., Boenicke, L., Sandberg, C., Beckmann, S., Bayer, E., Walczak, H., Kalthoff, H., & Ungefroren, H. (2000) · Oncogene · doi:10.1038/sj.onc.1203936 · Cited by 275
TRAIL receptor signalling and modulation: Are we on the right TRAIL?
Mahalingam, D., Szegezdi, E., Keane, M., Jong, S. D., & Samali, A. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.11.006 · Cited by 272
Nakata, S., Yoshida, T., Horinaka, M., Shiraishi, T., Wakada, M., & Sakai, T. (2004) · Oncogene · doi:10.1038/sj.onc.1207830 · Cited by 271
Zhai, Y., Guo, R., Hsu, T. L., Yu, G. L., Ni, J., Kwon, B. S., Jiang, G. W., Lu, J., Tan, J., Ugustus, M., et al. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3492 · Cited by 270
Stem and progenitor cell-mediated tumor selective gene therapy
Aboody, K. S., Najbauer, J., & Danks, M. K. (2008) · Gene Therapy · doi:10.1038/gt.2008.41 · Cited by 270
Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression
Isakov, N. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.04.012 · Cited by 270
Elevated Akt Activity Protects the Prostate Cancer Cell Line LNCaP from TRAIL-induced Apoptosis
Nesterov, A., Lu, X., Johnson, M., Miller, G. J., Ivashchenko, Y., & Kraft, A. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m005196200 · Cited by 269
Concepts of tissue injury and cell death in inflammation: a historical perspective
Wallach, D., Kang, T.-B., & Kovalenko, A. (2014) · Nature Reviews Immunology · doi:10.1038/nri3561 · Cited by 267
TRAIL/Apo-2-ligand-induced apoptosis in human T cells
Jeremias, I., Herr, I., Boehler, T., & Debatin, K.-M. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199801)28:01<143::aid-immu143>3.0.co;2-3 · Cited by 267
Monleón, I., Martínez-Lorenzo, M. J., Monteagudo, L., Lasierra, P., Taulés, M., Iturralde, M., Piñeiro, A., Larrad, L., Alava, M. A., Naval, J., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.12.6736 · Cited by 266
Bodmer, J.-L., Burns, K., Schneider, P., Hofmann, K., Steiner, V., Thome, M., Bornand, T., Hahne, M., Schröter, M., Becker, K., et al. (1997) · Immunity · doi:10.1016/s1074-7613(00)80244-7 · Cited by 264
RETRACTED: TRAIL identifies immature natural killer cells in newborn mice and adult mouse liver
Takeda, K., Cretney, E., Hayakawa, Y., Ota, T., Akiba, H., Ogasawara, K., Yagita, H., Kinoshita, K., Okumura, K., & Smyth, M. J. (2005) · Blood · doi:10.1182/blood-2004-08-3262 · Cited by 261
Retracted
Metadata
- Authors
- Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., & Ashkenazi, A.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1996-05
- Volume
- 271
- Issue
- 22
- Pages
- 12687-12690
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2056217426
- Cited by
- 1,793
- References
- 28
- FWCI
- 17.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.